Project Grant R41CA291231
Award Date
8/15/24
Completion Date
7/31/25
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Awardee
Sieyax, Inc. (U6SRN9B8HC53)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Westminster, CO 80023, USA
Similar Awards
This federal Project Grant award of $559,587.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate how thyroid hormone (TH) can suppress the growth of medulloblastoma (MB), the most common malignant brain tumor in children. The research aims to elucidate the mechanisms by which TH induces terminal differentiation of MB cells, thereby inhibiting their tumorigenic potential and repressing MB tumor growth. Key research activities include...
The National Cancer Institute (NCI) awarded a $219,351 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Institute For Cancer Research to assess the efficacy and toxicity of T3, the active form of thyroid hormone, as a potential treatment for medulloblastoma, the most common malignant brain tumor in children. The two-year project aims to: Evaluate the toxicity, pharmacokinetics, and pharmacodynamics of T3 in tumor-bearing mice, and Examine the therapeutic efficacy of T3 in...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides USD 477,576 to George Washington University to conduct research on the role of the SIRT1 protein in regulating centrosomal and ciliary biogenesis, and to explore the therapeutic potential of manipulating SIRT1 activity to treat Sonic Hedgehog subtype medulloblastoma, a difficult-to-treat cancer. The 5-year project aims to advance the fundamental understanding of SIRT1's function...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,200,000 to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The project aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant recurrent brain cancers and promotes tumor growth, immune evasion, and stem cell formation. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is focused on developing a "next-generation" precision adoptive T cell therapy approach to treat pediatric high-grade gliomas. The $474,656 award will fund research to evaluate the safety, efficacy, and immunological effects of this therapy in preclinical models, determine the capacity to isolate and expand antigen-specific T cells from pediatric patients, and conduct a Phase 1...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $644,967 to the University of Pittsburgh to conduct research on the role of SMARCD3/BAF60C in medulloblastoma, a type of brain cancer. The research aims to delineate how SMARCD3 regulation by MYC and EZH2 contributes to MYC-induced medulloblastoma formation and metastatic...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $417,858 to Brigham & Women's Hospital Inc. to develop novel cellular therapies for glioblastoma (GBM), a highly malignant brain tumor. The research aims to engineer mesenchymal stem cells (MSCs) to release bi-specific T cell engagers (BiTEs) targeting GBM antigens EGFR/EGFRvIII and IL13Rα2, and co-express IL-12 and PD-1 inhibitors to enhance T cell potency and...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...